First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways to treat autoimmune and inflammatory diseases. The company's pipeline includes three initial assets: ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter that completed Phase 2b testing for rheumatoid arthritis; and ANB101, a BDCA2 modulator in Phase 1a development. Headquartered in San Diego, California, First Tracks Biotherapeutics is a recently established independent company focused on advancing innovative antibody-based therapies to address significant unmet needs in autoimmune and inflammatory disease treatment. The company operates as a pure-play biopharmaceutical developer, concentrating exclusively on its targeted therapeutic programs.